Cervical cancer is the second most common type of cancer (17.8 per 100,000 women) and cause of cancer deaths (9.8 per 100,000) among all types of cancer in women in developing countries.42 percent of cases of cervical cancer are diagnosed in women prior to age 45 years.Most of their cancers are diagnosed at an early stage when survival is over 90 percent.Uterine cancer is the second most common gynecologic malignancy in developing countries with an incidence of 5.9 per 100,000 and a mortality rate of 1.7 per 100,000.Most endometrial cancers occur around or after menopause, 5% of all women are affected by the disease during their childbearing years.In early stage of the disease surgical cure rates are high.The standard therapy for endometrial carcinoma and cervical cancer includes hysterectomy which leads to loss of fertility.These young women with early stage low grade cancers may be candidates for fertility preservation options, such as radical trachelectomy, cervical conization, neoadjuvant chemotherapy and radical trachelectomy for cervical cancer and different forms of progestin hormonal therapy for endometrial cancer.Two-thirds of pregnancies following radical trachelectomy have ended in a live birth and 40 percent of the pregnancies resulted in a healthy newborn at term.The risk of recurrence (3-6%) and mortality (1%) is same as standard therapy for cervical cancer.In term of endometrial cancer 80% have been treated with medroxyprogesterone acetate and overall response rate of 76% and 50% were cancer free.Of those who relapsed (25%) they had second response in 75% of cases.In literature, median time of response was 12 weeks with average duration of treatment being 6 months.One third of women became pregnant and 35% of those required artificial reproductive technique because of associated infertility.